Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17
HOS-109484 · Präparat HOS-093201
16
Non-steroidal selective mineralocorticoid receptor (MR) antagonists
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0- 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax 114% needed.
Diclofenac AUC0- 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax 1.7-fold other long-acting opiates
Oxycodone AUC0- 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUC 47% reactions and toxicity related to
S-methadone Cmax 65% methadone, including QTc
S-methadone AUC 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0- 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0- 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUC 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax 14%
Voriconazole AUC 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 8ddbb18c489ccc11c6814ac36e2fb24fd816c63d5b15490877a83dbf46e7d7f5 · Zeichen 27474–31780 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 48–49
HOS-109554 · Präparat HOS-093201
48
Non-steroidal selective mineralocorticoid receptor (MR) antagonists
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0- 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax 114% needed.
Diclofenac AUC0- 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax 1.7-fold other long-acting opiates
Oxycodone AUC0- 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUC 47% reactions and toxicity related to
S-methadone Cmax 65% methadone, including QTc
S-methadone AUC 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0- 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0- 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUC 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax 14%
Voriconazole AUC 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage e6233d476ccce7daca52d1dd2aaaa91e8c3161bd371e92e18ca8a2257625f3c2 · Zeichen 27978–32284 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 80–81
HOS-109619 · Präparat HOS-093201
80
Non-steroidal selective mineralocorticoid receptor (MR) antagonists
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0- 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax 114% needed.
Diclofenac AUC0- 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax 1.7-fold other long-acting opiates
Oxycodone AUC0- 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUC 47% reactions and toxicity related to
S-methadone Cmax 65% methadone, including QTc
S-methadone AUC 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0- 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0- 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUC 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax 14%
Voriconazole AUC 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 5c1a7a3fda98976f51693be4906d67df598ab85a4fcf5f8cd51e8c0fe387196a · Zeichen 27504–31810 im Abschnitt
Wechselwirkungen · Lyrica
Lyrica 25 mg hard capsules Lyrica 50 mg hard capsules Lyrica 75 mg hard capsules Lyrica 100 mg hard capsules Lyrica 150 mg hard capsules Lyrica 200 mg hard capsules Lyrica 225 mg hard capsules Lyrica 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-112896 · Präparat HOS-093785
In vivo studies and population pharmacokinetic analysis
Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed
between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam,
oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics,
insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin
clearance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) tiagabine (HOS-112899) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) oxycodone (HOS-109487) lorazepam (HOS-085981) gabapentin (HOS-090745) ethanol (HOS-089988) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:23:00Z · SHA-256 b911bddbab432f8a0fcedb9c67537bff55e0bf53d314c31c88869bca834605af · Passage da089224ea0ec4abc0cbed18c715ba22143350e7ab711c5dc56268bbae3381d5 · Zeichen 317–785 im Abschnitt
Wechselwirkungen · Lyrica
Lyrica 25 mg hard capsules Lyrica 50 mg hard capsules Lyrica 75 mg hard capsules Lyrica 100 mg hard capsules Lyrica 150 mg hard capsules Lyrica 200 mg hard capsules Lyrica 225 mg hard capsules Lyrica 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-112902 · Präparat HOS-093785
In the postmarketing experience, there are reports of respiratory failure, coma and deaths in patients
taking pregabalin and opioids and/or other central nervous system (CNS) depressant medicinal
products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function
caused by oxycodone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxycodone (HOS-109487)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:23:00Z · SHA-256 b911bddbab432f8a0fcedb9c67537bff55e0bf53d314c31c88869bca834605af · Passage 4a33bdabdd55eaf2dcb1fc5914a87ba24a9543b80086d57d33957e486a06efb8 · Zeichen 1143–1459 im Abschnitt
Wechselwirkungen · Lyrica
Lyrica 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 24
HOS-112918 · Präparat HOS-093785
In vivo studies and population pharmacokinetic analysis
Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed
between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam,
oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics,
insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin
clearance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) tiagabine (HOS-112899) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) oxycodone (HOS-109487) lorazepam (HOS-085981) gabapentin (HOS-090745) ethanol (HOS-089988) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:23:00Z · SHA-256 b911bddbab432f8a0fcedb9c67537bff55e0bf53d314c31c88869bca834605af · Passage da089224ea0ec4abc0cbed18c715ba22143350e7ab711c5dc56268bbae3381d5 · Zeichen 317–785 im Abschnitt
Wechselwirkungen · Lyrica
Lyrica 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 24–25
HOS-112921 · Präparat HOS-093785
24
In the postmarketing experience, there are reports of respiratory failure, coma and deaths in patients
taking pregabalin and opioids and/or other central nervous system (CNS) depressant medicinal
products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function
caused by oxycodone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxycodone (HOS-109487)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:23:00Z · SHA-256 b911bddbab432f8a0fcedb9c67537bff55e0bf53d314c31c88869bca834605af · Passage 646e551b947d60dc630369c1e78783c48cd2abf8e23612fe33783550ebfb2c8d · Zeichen 1195–1515 im Abschnitt
Wechselwirkungen · Lyrica
Lyrica 25 mg orodispersible tablets Lyrica 75 mg orodispersible tablets Lyrica 150 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 40
HOS-112937 · Präparat HOS-093785
In vivo studies and population pharmacokinetic analysis
Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed
between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam,
oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics,
insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin
clearance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) tiagabine (HOS-112899) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) oxycodone (HOS-109487) lorazepam (HOS-085981) gabapentin (HOS-090745) ethanol (HOS-089988) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:23:00Z · SHA-256 b911bddbab432f8a0fcedb9c67537bff55e0bf53d314c31c88869bca834605af · Passage da089224ea0ec4abc0cbed18c715ba22143350e7ab711c5dc56268bbae3381d5 · Zeichen 317–785 im Abschnitt
Wechselwirkungen · Lyrica
Lyrica 25 mg orodispersible tablets Lyrica 75 mg orodispersible tablets Lyrica 150 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 41
HOS-112940 · Präparat HOS-093785
In the postmarketing experience, there are reports of respiratory failure, coma and deaths in patients
taking pregabalin and opioids and/or other central nervous system (CNS) depressant medicinal
products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function
caused by oxycodone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxycodone (HOS-109487)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:23:00Z · SHA-256 b911bddbab432f8a0fcedb9c67537bff55e0bf53d314c31c88869bca834605af · Passage 4a33bdabdd55eaf2dcb1fc5914a87ba24a9543b80086d57d33957e486a06efb8 · Zeichen 1198–1514 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 22–23
HOS-116419 · Präparat HOS-094447
22
Fentanyl Based on theoretical considerations Clinical monitoring is
Oxycodone boosted PREZISTA may increase plasma recommended when
Tramadol concentrations of these analgesics. co-administering boosted
(CYP2D6 and/or CYP3A inhibition) PREZISTA with these analgesics.
OESTROGEN-BASED CONTRACEPTIVES
Drospirenone drospirenone AUC ↑ 58%€ When PREZISTA is
Ethinylestradiol drospirenone Cmin ND€ co-administered with a
(3 mg/0.02 mg once drospirenone Cmax ↑ 15%€ drospirenone-containing product,
daily) ethinylestradiol AUC 30%€ clinical monitoring is
recommended due to the potential
ethinylestradiol Cmin ND€
for hyperkalaemia.
ethinylestradiol Cmax 14%€
€
with darunavir/cobicistat Alternative or additional
contraceptive measures are
Ethinylestradiol ethinylestradiol AUC ↓ 44%β recommended when
Norethindrone ethinylestradiol Cmin ↓ 62%β oestrogen-based contraceptives are
35 g/1 mg once daily ethinylestradiol Cmax ↓ 32%β co-administered with boosted
norethindrone AUC ↓ 14%β PREZISTA. Patients using
norethindrone Cmin ↓ 30%β oestrogens as hormone
norethindrone Cmax ↔β replacement therapy should be
β
with darunavir/ritonavir clinically monitored for signs of
oestrogen deficiency.
OPIOID ANTAGONIST
Naloxegol Not studied. Co-administration of boosted
PREZISTA and naloxegol is
contraindicated.
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS
For the treatment of In an interaction study #, a comparable The combination of avanafil and
erectile dysfunction systemic exposure to sildenafil was boosted PREZISTA is
Avanafil observed for a single intake of 100 mg contraindicated (see section 4.3).
Sildenafil sildenafil alone and a single intake of Concomitant use of other PDE-5
Tadalafil 25 mg sildenafil co-administered with inhibitors for the treatment of
Vardenafil PREZISTA and low dose ritonavir. erectile dysfunction with boosted
PREZISTA should be done with
caution. If concomitant use of
boosted PREZISTA with
sildenafil, vardenafil or tadalafil is
indicated, sildenafil at a single
dose not exceeding 25 mg in
48 hours, vardenafil at a single
dose not exceeding 2.5 mg in
72 hours or tadalafil at a single
dose not exceeding 10 mg in
72 hours is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) oxycodone (HOS-109487) cobicistat (HOS-088111) avanafil (HOS-086161) drospirenone (HOS-116422) naloxegol (HOS-109428) norethindrone (HOS-088136) sildenafil (HOS-086162) fentanyl (HOS-086196) ritonavir (HOS-084521) vardenafil (HOS-086163) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 46fd073076a452542b46d19575ef31721f4438f76a3fc3b4ddbcf4388fa73f42 · Zeichen 68873–72741 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 64–65
HOS-116530 · Präparat HOS-094447
64
Buprenorphine/naloxone buprenorphine AUC ↓ 11% The clinical relevance of the
8/2 mg–16/4 mg once buprenorphine Cmin ↔ increase in norbuprenorphine
daily buprenorphine Cmax ↓ 8% pharmacokinetic parameters has
norbuprenorphine AUC ↑ 46% not been established. Dose
norbuprenorphine Cmin ↑ 71% adjustment for buprenorphine may
norbuprenorphine Cmax ↑ 36% not be necessary when
naloxone AUC ↔ co-administered with
PREZISTA/ritonavir but a careful
naloxone Cmin ND
clinical monitoring for signs of
naloxone Cmax ↔ opiate toxicity is recommended.
Fentanyl Based on theoretical considerations Clinical monitoring is
Oxycodone boosted PREZISTA may increase plasma recommended when
Tramadol concentrations of these analgesics. co-administering boosted
(CYP2D6 and/or CYP3A inhibition) PREZISTA with these analgesics.
OESTROGEN-BASED CONTRACEPTIVES
Drospirenone Not studied with darunavir/ritonavir. When PREZISTA is co-
Ethinylestradiol administered with a drospirenone-
(3 mg/0.02 mg once containing product, clinical
daily) monitoring is recommended due to
the potential for hyperkalaemia.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxycodone (HOS-109487) buprenorphine (HOS-086193) drospirenone (HOS-116422) naloxone (HOS-109490) fentanyl (HOS-086196) ritonavir (HOS-084521) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 56b25c90f6cb41a8b0508e6878b269d07fd21a58c18cd802b3386bab4e59a687 · Zeichen 58924–60736 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 104–105
HOS-116620 · Präparat HOS-094447
104
Fentanyl Based on theoretical considerations Clinical monitoring is
Oxycodone boosted PREZISTA may increase plasma recommended when
Tramadol concentrations of these analgesics. co-administering boosted
(CYP2D6 and/or CYP3A inhibition) PREZISTA with these analgesics.
OESTROGEN-BASED CONTRACEPTIVES
Drospirenone drospirenone AUC ↑ 58%€ When PREZISTA is co-
Ethinylestradiol drospirenone Cmin ND€ administered with a drospirenone-
(3 mg/0.02 mg once drospirenone Cmax ↑ 15%€ containing product, clinical
daily) ethinylestradiol AUC 30%€ monitoring is recommended due to
the potential for hyperkalaemia.
ethinylestradiol Cmin ND€
ethinylestradiol Cmax 14%€ Alternative or additional
€
with darunavir/cobicistat contraceptive measures are
recommended when
Ethinylestradiol ethinylestradiol AUC ↓ 44%β oestrogen-based contraceptives are
Norethindrone ethinylestradiol Cmin ↓ 62%β co-administered with boosted
35 g/1 mg once daily ethinylestradiol Cmax ↓ 32%β PREZISTA. Patients using
norethindrone AUC ↓ 14%β oestrogens as hormone
norethindrone Cmin ↓ 30%β replacement therapy should be
norethindrone Cmax ↔β clinically monitored for signs of
β
with darunavir/ritonavir oestrogen deficiency.
OPIOID ANTAGONIST
Naloxegol Not studied. Co-administration of boosted
PREZISTA and naloxegol is
contraindicated.
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS
For the treatment of In an interaction study #, a comparable The combination of avanafil and
erectile dysfunction systemic exposure to sildenafil was boosted PREZISTA is
Avanafil observed for a single intake of 100 mg contraindicated (see section 4.3).
Sildenafil sildenafil alone and a single intake of Concomitant use of other PDE-5
Tadalafil 25 mg sildenafil co-administered with inhibitors for the treatment of
Vardenafil PREZISTA and low dose ritonavir. erectile dysfunction with boosted
PREZISTA should be done with
caution. If concomitant use of
boosted PREZISTA with
sildenafil, vardenafil or tadalafil is
indicated, sildenafil at a single
dose not exceeding 25 mg in
48 hours, vardenafil at a single
dose not exceeding 2.5 mg in
72 hours or tadalafil at a single
dose not exceeding 10 mg in
72 hours is recommended.
For the treatment of Not studied. Concomitant use of A safe and effective dose of
pulmonary arterial sildenafil or tadalafil for the treatment of sildenafil for the treatment of
hypertension pulmonary arterial hypertension and pulmonary arterial hypertension
Sildenafil boosted PREZISTA may increase plasma co-administered with boosted
Tadalafil concentrations of sildenafil or tadalafil. PREZISTA has not been
(CYP3A inhibition) established. There is an increased
potential for sildenafil-associated
adverse events (including visual
disturbances, hypotension,
prolonged erection and syncope).
Therefore, co-administration of
boosted PREZISTA and sildenafil
when used for the treatment of
pulmonary arterial hypertension is
contraindicated (see section 4.3).
Co-administration of tadalafil for
the treatment of pulmonary arterial
hypertension with boosted
PREZISTA is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) oxycodone (HOS-109487) cobicistat (HOS-088111) avanafil (HOS-086161) drospirenone (HOS-116422) naloxegol (HOS-109428) norethindrone (HOS-088136) sildenafil (HOS-086162) fentanyl (HOS-086196) ritonavir (HOS-084521) vardenafil (HOS-086163) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 53e0febc21778baf0cd734e4641645b6ed035e132d52ecd7b62207df9c2eaa53 · Zeichen 68281–74416 im Abschnitt
Wechselwirkungen · Zytiga
ZYTIGA 250 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-125282 · Präparat HOS-096037
Caution is advised when administering with medicinal products activated by or metabolised by
CYP2D6, particularly with medicinal products that have a narrow therapeutic index. Dose reduction of
medicinal products with a narrow therapeutic index that are metabolised by CYP2D6 should be
considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol,
propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine,
oxycodone and tramadol (the latter three medicinal products requiring CYP2D6 to form their active
analgesic metabolites).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) codeine (HOS-090544) desipramine (HOS-086249) flecainide (HOS-086203) oxycodone (HOS-109487) risperidone (HOS-086280) venlafaxine (HOS-086573) haloperidol (HOS-085602) propranolol (HOS-084529) metoprolol (HOS-090094) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 0f93936cb2f4b0a901b74791dc0ebac57b0490ee048860943323df74f2965713 · Zeichen 1565–2156 im Abschnitt
Wechselwirkungen · Zytiga
ZYTIGA 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-125314 · Präparat HOS-096037
Caution is advised when administering with medicinal products activated by or metabolised by
CYP2D6, particularly with medicinal products that have a narrow therapeutic index. Dose reduction of
medicinal products with a narrow therapeutic index that are metabolised by CYP2D6 should be
considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol,
propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine,
oxycodone and tramadol (the latter three medicinal products requiring CYP2D6 to form their active
analgesic metabolites).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) codeine (HOS-090544) desipramine (HOS-086249) flecainide (HOS-086203) oxycodone (HOS-109487) risperidone (HOS-086280) venlafaxine (HOS-086573) haloperidol (HOS-085602) propranolol (HOS-084529) metoprolol (HOS-090094) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T14:31:00Z · SHA-256 1cd8edc18fae83339cc466c58b27be12ff13a584e8ad30419a21aea3ec2adf1f · Passage 0f93936cb2f4b0a901b74791dc0ebac57b0490ee048860943323df74f2965713 · Zeichen 1565–2156 im Abschnitt
Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 17–18
HOS-130968 · Präparat HOS-096981
17
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax ↑ 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-∞ ↑ 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax ↑ 114% needed.
Diclofenac AUC0-∞ ↑ 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax ↑ 1.7-fold other long-acting opiates
Oxycodone AUC0-∞ ↑ 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax ↑ 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUCτ ↑ 47% reactions and toxicity related to
S-methadone Cmax ↑ 65% methadone, including QTc
S-methadone AUCτ ↑ 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0-∞ ↑ 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 µg/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0-∞ ↑ 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax ↑ 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUCτ ↑ 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax ↑ 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUCτ ↑ 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax ↑ 14%
Voriconazole AUCτ ↑ 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage c15a75c62801770f9555f6206fed29c8569fb1a5f9063364f5ddb780efc68271 · Zeichen 27899–32111 im Abschnitt
Wechselwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)
Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-132656 · Präparat HOS-097274
In vivo studies and population pharmacokinetic analysis
Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed
between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam,
oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics,
insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin
clearance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) tiagabine (HOS-112899) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) oxycodone (HOS-109487) lorazepam (HOS-085981) gabapentin (HOS-090745) ethanol (HOS-089988) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage da089224ea0ec4abc0cbed18c715ba22143350e7ab711c5dc56268bbae3381d5 · Zeichen 317–785 im Abschnitt
Wechselwirkungen · Pregabalin Viatris Pharma (previously Pregabalin Pfizer)
Pregabalin Viatris Pharma 25 mg hard capsules Pregabalin Viatris Pharma 50 mg hard capsules Pregabalin Viatris Pharma 75 mg hard capsules Pregabalin Viatris Pharma 100 mg hard capsules Pregabalin Viatris Pharma 150 mg hard capsules Pregabalin Viatris Pharma 200 mg hard capsules Pregabalin Viatris Pharma 225 mg hard capsules Pregabalin Viatris Pharma 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-132663 · Präparat HOS-097274
In the postmarketing experience, there are reports of respiratory failure, coma and deaths in patients
taking pregabalin and opioids and/or other central nervous system (CNS) depressant medicinal
products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function
caused by oxycodone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxycodone (HOS-109487)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-24T15:36:00Z · SHA-256 82ee888afd9191364ca2885cfe33f3a6014857efdff1de95ea2361849731a42c · Passage 4a33bdabdd55eaf2dcb1fc5914a87ba24a9543b80086d57d33957e486a06efb8 · Zeichen 1143–1459 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-132854 · Präparat HOS-097310
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Analgesic opioid
Methadone Potential ↑ in plasma concentrations of Contraindicated due to the increased
methadone risk of serious cardiovascular events
including QT prolongation and
torsade de pointes, or respiratory or
CNS depression (see section 4.3).
Buprenorphine IV and Buprenorphine: Careful monitoring.
sublingual AUC: ↑ 1.5-fold The buprenorphine dose should be
Cmax: ↑1.7-fold adjusted.
Alfentanil, fentanyl Potential ↑in plasma concentrations of Careful monitoring of adverse
alfentanil and fentanyl reactions (respiratory depression,
sedation) is recommended. It may be
necessary to lower the dose of
alfentanil and fentanyl.
Oxycodone ↑in plasma concentrations of oxycodone Careful monitoring.
have been observed The oxycodone dose may be
adjusted.
Antiarrhythmics
Disopyramide Potential ↑in plasma concentrations of Contraindicated due to the risk of
Quinidine disopyramide and quinidine serious cardiovascular events
including QT prolongation (see
Dronedarone Repeated doses of 200 mg ketoconazole section 4.3).
daily resulted in a 17-fold increase in
dronedarone exposure
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) dronedarone (HOS-086144) methadone (HOS-086198) oxycodone (HOS-109487) quinidine (HOS-085593) buprenorphine (HOS-086193) disopyramide (HOS-085595) fentanyl (HOS-086196)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage a1dd81238eab9495ccc07c3bae05807a0a25b388887cce3d7c2818dcf0cb8b03 · Zeichen 5148–7488 im Abschnitt
Wechselwirkungen · Pregabalin Sandoz
Pregabalin Sandoz 25 mg hard capsules Pregabalin Sandoz 50 mg hard capsules Pregabalin Sandoz 75 mg hard capsules Pregabalin Sandoz 100 mg hard capsules Pregabalin Sandoz 150 mg hard capsules Pregabalin Sandoz 200 mg hard capsules Pregabalin Sandoz 225 mg hard capsules Pregabalin Sandoz 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-133709 · Präparat HOS-097488
In vivo studies and population pharmacokinetic analysis
Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed
between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam,
oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics,
insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin
clearance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) tiagabine (HOS-112899) topiramate (HOS-110310) phenobarbital (HOS-085617) valproic acid (HOS-088515) carbamazepine (HOS-085618) oxycodone (HOS-109487) lorazepam (HOS-085981) gabapentin (HOS-090745) ethanol (HOS-089988) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T15:55:00Z · SHA-256 cf6544444859a0bf688557553e6f137bac82b24f016c6d9cb4756ad6de2112ce · Passage da089224ea0ec4abc0cbed18c715ba22143350e7ab711c5dc56268bbae3381d5 · Zeichen 317–785 im Abschnitt
Wechselwirkungen · Pregabalin Sandoz
Pregabalin Sandoz 25 mg hard capsules Pregabalin Sandoz 50 mg hard capsules Pregabalin Sandoz 75 mg hard capsules Pregabalin Sandoz 100 mg hard capsules Pregabalin Sandoz 150 mg hard capsules Pregabalin Sandoz 200 mg hard capsules Pregabalin Sandoz 225 mg hard capsules Pregabalin Sandoz 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7–8
HOS-133719 · Präparat HOS-097488
In the postmarketing experience, there are reports of respiratory failure, coma and deaths in patients
taking pregabalin and opioids and/or other central nervous system (CNS) depressant medicinal
products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function
caused by oxycodone.
7
Interactions and the elderly
No specific pharmacodynamic interaction studies were conducted in elderly volunteers. Interaction
studies have only been performed in adults.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): oxycodone (HOS-109487)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T15:55:00Z · SHA-256 cf6544444859a0bf688557553e6f137bac82b24f016c6d9cb4756ad6de2112ce · Passage 579330512077637a9d00a1dd7cf3d8c41c8042eee3ad17302a35d6949fd1895b · Zeichen 1143–1684 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.